Posted by Michael Wonder on 27 Jan 2026
Drug Farm announces FDA fast track designation for first in class ALPK1 inhibitor DF-003 for the treatment of ROSAH syndrome
27 January 2026 - Drug Farm today announced that the US FDA has granted fast track designation to DF-003, its investigational, first in class ALPK1 inhibitor, for the treatment of ROSAH syndrome, a rare, autosomal dominant auto-inflammatory disease with no approved therapies.
DF-003 is a structurally novel, orally administered small molecule inhibitor that potently and selectively inhibits disease-causing mutant ALPK1, including the ROSAH-associated ALPK1 T237M variant.
